Why the study?
Does iodixanol 270 mg I/ml provide comparable efficacy and safety to iohexol 300 mg I/ml in patients undergoing abdominal intra-arterial DSA?
Does iodixanol 270 mg I/ml provide comparable efficacy and safety to iohexol 300 mg I/ml in patients undergoing abdominal intra-arterial DSA?
Iodixanol 270 mg I/ml provides comparable diagnostic efficacy and safety to iohexol 300 mg I/ml in abdominal intra-arterial DSA, with potentially less pronounced effects on renal function markers.
Supports iodixanol 270 as alternative to iohexol 300 in abdominal DSA; confirms comparable efficacy with potentially better renal tolerance.
The safety, tolerability and efficacy of iodixanol 270 mg I/ml were compared to those of iohexol 300 mg I/ml in a double-blind, randomized, parallel abdominal intra-arterial DSA phase III trial. Fifty-nine patients were included in the trial; 39 patients received iodixanol and 20 received iohexol. the mean volume of iodixanol administered was 235.8 ml (0.93 g I/kg b.w.) while the mean volume of iohexol was 254.7 ml (1.10 g I/kg b.w.). No differences in diagnostic information and radiographic density were apparent in spite of the difference in the concentration of iodine. No serious adverse events occurred. Four patients (10%) in the iodixanol group and 2 (10%) in the iohexol group experienced adverse events. Eight percent of the injections of iodixanol promoted discomfort, compared to 12% of the injections of iohexol. An increase in S-urea and S-creatinine was seen with both agents the first day after injection, but appeared to be less pronounced with iodixanol than with iohexol. Other serum tests reveale...
No takes yet. Share an insight, caveat, or question.
Singh et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: